Back to Search
Start Over
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner
- Source :
- Dimopoulos, K, Søgaard Helbo, A, Fibiger Munch-Petersen, H, Sjö, L, Christensen, J, Sommer Kristensen, L, Asmar, F, Hermansen, N E U, O'Connel, C, Gimsing, P, Liang, G & Grønbaek, K 2018, ' Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner ', Molecular Oncology, vol. 12, no. 2, pp. 180-195 . https://doi.org/10.1002/1878-0261.12157, Molecular Oncology, Molecular Oncology, Vol 12, Iss 2, Pp 180-195 (2018), Dimopoulos, K, Søgaard Helbo, A, Fibiger Munch-Petersen, H, Sjö, L, Christensen, J, Sommer Kristensen, L, Asmar, F, Hermansen, N E U, O'Connel, C, Gimsing, P, Liang, G & Grønbaek, K 2018, ' Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner ', Molecular Oncology, vol. 12, no. 2 . https://doi.org/10.1002/1878-0261.12157
- Publication Year :
- 2017
- Publisher :
- Wiley, 2017.
-
Abstract
- Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of action. In an effort to comprehend the precise mechanisms behind the development of IMiD resistance and examine whether it is potentially reversible, we established lenalidomide- (-LR) and pomalidomide-resistant (-PR) human myeloma cell lines from two IMiD-sensitive cell lines, OPM2 and NCI-H929, by continuous culture in the presence of lenalidomide or pomalidomide for 4-6 months, until acquirement of stable resistance. By assessing genome-wide DNA methylation and chromatin accessibility in these cell lines, we found that acquired IMiD-resistance is associated with an increase of genome-wide DNA methylation and an even greater reduction of chromatin accessibility. Transcriptome analysis confirmed that resistant cell lines are mainly characterized by a reduction in gene expression, identifying SMAD3 as a commonly downregulated gene in IMiD-resistant cell lines. Moreover, we show that these changes are potentially reversible, since combination of 5-Azacytidine and EPZ-6438 not only restored the observed accessibility changes and the expression of SMAD3, but also resensitized the resistant cells to both lenalidomide and pomalidomide. Interestingly, the resensitization process was independent of CRBN. Our data suggest that simultaneous inhibition of DNA methyl-transferases (DNMTs) and EZH2 leads to an extensive epigenetic reprogramming which allows myeloma cells to (re)gain sensitivity to IMiDs.
- Subjects :
- 0301 basic medicine
Cancer Research
Gene Expression
0302 clinical medicine
Lenalidomide
Research Articles
Multiple myeloma
5‐azacytidine
cereblon
General Medicine
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Chromatin
Thalidomide
multiple myeloma
Oncology
030220 oncology & carcinogenesis
Benzamides
DNA methylation
Azacitidine
Molecular Medicine
Reprogramming
Research Article
medicine.drug
Pyridones
Morpholines
Ubiquitin-Protein Ligases
Biology
lcsh:RC254-282
03 medical and health sciences
immunomodulatory drugs
Cell Line, Tumor
Journal Article
Genetics
medicine
Humans
Enhancer of Zeste Homolog 2 Protein
Epigenetics
Adaptor Proteins, Signal Transducing
epigenetics
Gene Expression Profiling
Cereblon
Biphenyl Compounds
DNA Methylation
Pomalidomide
medicine.disease
Molecular biology
030104 developmental biology
Drug Resistance, Neoplasm
Cancer research
Peptide Hydrolases
Subjects
Details
- ISSN :
- 15747891
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Molecular Oncology
- Accession number :
- edsair.doi.dedup.....e83dac78444f1a137d42b38da96d302e